Qiagen (NYSE:QGEN) Updates FY 2025 Earnings Guidance

Qiagen (NYSE:QGEN) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 2.280- for the period, compared to the consensus EPS estimate of 2.350. The company issued revenue guidance of $2.1 billion-, compared to the consensus revenue estimate of $2.1 billion. Qiagen also updated its Q1 2025 guidance to 0.500- EPS.

Qiagen Stock Performance

Shares of Qiagen stock traded up $0.40 on Wednesday, reaching $43.76. 1,533,236 shares of the company traded hands, compared to its average volume of 1,163,455. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. The firm has a market capitalization of $9.71 billion, a PE ratio of 109.09, a PEG ratio of 3.10 and a beta of 0.36. The company has a 50 day moving average of $43.78 and a 200 day moving average of $43.25. Qiagen has a 52 week low of $40.15 and a 52 week high of $49.30.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.73% and a return on equity of 13.43%. Equities analysts forecast that Qiagen will post 2.23 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on QGEN. Morgan Stanley restated an “equal weight” rating and set a $46.67 price target (down from $48.61) on shares of Qiagen in a research report on Monday, January 6th. Jefferies Financial Group reiterated a “buy” rating and issued a $52.50 target price (up from $40.83) on shares of Qiagen in a research report on Tuesday, December 10th. HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $47.64 target price on the stock. in a research note on Thursday, October 17th. Finally, Hsbc Global Res raised Qiagen to a “hold” rating in a research note on Thursday, October 17th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.07.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.